Loading stock data…
RLAY
$12.72-0.24 (-1.85%)
Market ClosedLast close May 1
Relay Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Relay Therapeutics, Inc. in the Healthcare sector is trading at $12.72. The stock is currently 27% below its 52-week high of $17.32, remaining 66.9% above its 200-day moving average. Technical signals show neutral RSI of 35 and bearish MACD signal, explaining why RLAY maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 35) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$12.72
Potential Upside
5%
Whystock Fair Value$13.36
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$21.00+65.1%
Range$18.00 – $25.00
Fundamentals
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The compa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.76B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.58
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-48.76%
Volume
Today's trading volume
2.91M
Recent News
Relay Therapeutics Advances Zovegalisib To Phase 3 As Valuation Gap Persists
Relay Therapeutics (NasdaqGM:RLAY) plans to move its lead program, zovegalisib, into Phase 3 development for frontline PI3Ka mutated HR+/HER2- metastatic breast cancer. The decision is based on new clinical data that report encouraging efficacy and a manageable safety profile in heavily pre treated patients. Zovegalisib is described as an allosteric, pan mutant, isoform selective PI3Ka inhibitor enabled by Relay Therapeutics’ proprietary precision oncology platform. For Relay Therapeutics,...
Ardelyx (ARDX) Reports Q1 Loss, Beats Revenue Estimates
Ardelyx (ARDX) delivered earnings and revenue surprises of -15.39% and +3.24%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Relay Therapeutics (RLAY) Falls Hard on Profit-Taking From 74% April Jump
Relay Therapeutics Inc. (NASDAQ:RLAY) is one of the 10 Stocks Reeling From Huge Losses. Relay Therapeutics dropped for a second day on Tuesday, slashing 12.84 percent to finish at $13.03 apiece, as investors appeared to have taken profits after already jumping by 74 percent this month, thanks to positive data from its cancer treatment candidate, […]
Relay Therapeutics Unveils Zovegalisib Triplet Data, Signs Pfizer Supply Deal for Phase III Plan
Relay Therapeutics (NASDAQ:RLAY) outlined new data and development plans for its lead oncology program, zovegalisib, during a “frontline breast cancer update” conference call, highlighting encouraging activity and tolerability from a triplet regimen in heavily pretreated metastatic breast cancer pat
JonesResearch Initiates Coverage of Relay Therapeutics (RLAY) With a Hold Rating
Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the best low priced biotech stocks to invest in. On April 13, JonesResearch initiated coverage of Relay Therapeutics, Inc. (NASDAQ:RLAY) with a Hold rating and $18 price target. The firm stated that it has a bullish outlook for the company’s pipeline and zovegalisib’s prospects, and cited valuation for the […]